Elevian

About Elevian

Elevian is a biopharmaceutical company focused on developing medicines that restore regenerative capacity to treat and prevent aging-related diseases. Their lead program centers on a recombinant protein, rGDF11, designed to promote recovery after stroke by stimulating neovascularization, neurogenesis, and reducing inflammation. The company aims to extend healthspan by enabling regeneration in the brain and other organ systems, with research spanning cardiovascular, neurological, metabolic, pulmonary, renal, inflammatory, and skeletal muscle dysfunction. Based in Allston, Massachusetts, Elevian collaborates with a network of scientists and clinical advisors to translate regenerative biology into therapies for aging populations.